11
Chien Hsing Chang, David M Goldenberg, William J McBride, Edmund A Rossi: Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses. IBC Pharmaceuticals, Richard A Nakashima, June 23, 2009: US07550143 (70 worldwide citation)

The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached ...


12
David M Goldenberg, Hans J Hansen: Immunotherapy of autoimmune disorders using antibodies which target B-cells. Immunomedics, Faegre & Benson, July 11, 2006: US07074403 (70 worldwide citation)

Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion protei ...


13
Chien Hsing Chang, David M Goldenberg, William J McBride, Edmund A Rossi: PEGylation by the dock and lock (DNL) technique. IBC Pharmaceuticals, Richard A Nakashima, February 23, 2010: US07666400 (68 worldwide citation)

The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a therapeutic agent to a DDD sequence and attaching a PEG moiety to a ...


14
Susanna M Rybak, Dianne L Newton, David M Goldenberg: Immunotoxins directed against malignant cells. Immunomedics, May 28, 2002: US06395276 (61 worldwide citation)

The present invention relates to immunotoxins, that effectively kill malignant cells having a given surface marker and nucleic acid constructs encoding them. These reagents comprise a toxic moiety that is derived from a


15
David M Goldenberg: Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype. Immunomedics, Foley & Lardner, December 16, 1997: US05698178 (60 worldwide citation)

Polyspecific immunoconjugates and antibody composites that bind a multidrug transporter protein and an antigen associated with a tumor or infectious agent are used to overcome the multidrug resistant phenotype. These immunoconjugates and composites also can be used diagnostically to determine whethe ...


16
Serengulam V Govindan, David M Goldenberg, Sung Ju Moon: Camptothecin-binding moiety conjugates. Immunomedics, Richard A Nakashima, September 22, 2009: US07591994 (56 worldwide citation)

The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjuga ...


17
David M Goldenberg, Hans J Hansen, Shui on Leung: Chimeric, human and humanized anti-granulocyte antibodies and methods of use. Immunomedics, Richard A Nakashima, June 2, 2009: US07541440 (54 worldwide citation)

The present invention provides humanized, chimeric and human MN3 antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of granulocyte related disor ...


18
Chien Hsing Chang, David M Goldenberg: Dock-and-lock (DNL) vaccines for cancer therapy. IBC Pharmaceuticals, Richard A Nakashima, March 8, 2011: US07901680 (44 worldwide citation)

The present invention concerns methods and compositions for forming anti-cancer vaccine DNL complexes using dock-and-lock technology. In preferred embodiments, the anti-cancer vaccine DNL complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-bin ...


19
David M Goldenberg, Hans J Hansen: Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins. Immunomedics, Rossi Kimms & McDowell, May 19, 2009: US07534427 (43 worldwide citation)

The invention is directed to a method for treating a treating and diagnosing a B cell-related disease, T cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially administering to the mammal a therapeutic composition that comprises a pharmaceutically acceptable vehicl ...


20
Hans J Hansen, Zhengxing Qu, David M Goldenberg: Internalizing anti-CD74 antibodies and methods of use. Immunomedics, Richard A Nakashima, August 10, 2010: US07772373 (43 worldwide citation)

The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B ...